Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
74.70    0.80 (1.08%)
Bid:
74.60
Ask:
74.80
Spread: 0.20 (0.268%)
Market Cap: £714.94m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Director/PDMR Shareholding

4 Jul 2023 09:00

RNS Number : 8142E
Dr. Martens PLC
04 July 2023
 

Dr. Martens plc (the 'Company')

Director/PDMR Shareholding

Notification of Transactions by Directors/Persons Discharging Managerial Responsibility

The Company announces that on 30 June 2023 the following director / person discharging managerial responsibility ('PDMR') was granted a Performance Share Award (the 'Award') under the Company's Long Term Incentive Plan (the 'LTIP').

 

PDMR

Number of Shares

Kenny Wilson

1,541,114

 

The Award will vest subject to the achievement of earnings per share (67% weighting) and relative total shareholder return (33% weighting) targets over three years and, on vesting, will be subject to a further two-year holding period. In recognition of the lower share price since the last grant, the grant percentage has been scaled back from the normal policy level of 300% to 250% of base salary.

No consideration was paid for the grant of the Award and no price is payable on the exercise of the Award.

Recognising the outlook over the performance period, with profitability impacted by investments to underpin future growth and continuing economic uncertainty, the Company's Remuneration Committee has set the target range for EPS at a lower growth level than the EPS range in previous years, to provide the appropriate balance between setting targets that are achievable, but at the same time ambitious. The target range is three-year EPS CAGR of between 3% to 11%, against the base year of FY23. The target range for EPS is, in the view of the Remuneration Committee, equivalently stretching to the range set in prior years. The target range recognises the anticipated shape of the earnings trajectory, including the challenges of FY24.

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Kenny Wilson

2

Reason for the notification

a)

Position/status

PDMR (Chief Executive Officer)

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Dr. Martens plc

b)

LEI

213800QPT8YM6NQZPH28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of GBP 0.01

ISIN: GB00BL6NGV24

b)

Nature of the transaction

Grant of performance share award under the Dr. Martens Long Term Incentive Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

Nil

1,541,114

d)

Aggregated information

-

Aggregated volume

-

Price

 

 

1,541,114

Nil

e)

Date of the transaction

30 June 2023

f)

Place of the transaction

Outside of a trading venue

 

For further information, please contact:Paul Rolling, Assistant Company Secretary+447584243562

Bethany Barnes, Director of Investor Relations+447825187465

ENDS

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUORNROVUBRAR
Date   Source Headline
11th Jul 202411:05 amRNSResult of AGM
11th Jul 20247:00 amRNSAGM Trading Update
1st Jul 202412:44 pmRNSTotal Voting Rights
18th Jun 202412:00 pmRNSBlock listing Interim Review
14th Jun 202412:51 pmRNSDirector/PDMR Shareholding
14th Jun 202412:50 pmRNSDirector/PDMR Shareholding
12th Jun 20244:35 pmRNSTechnical change in Permira ownership structure
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 202412:20 pmRNSDirector/PDMR Shareholding
12th Jun 20249:00 amRNSAnnual Financial Report
3rd Jun 20249:00 amRNSDirector/PDMR Shareholding
3rd Jun 20249:00 amRNSCompany Secretary Change
31st May 20247:00 amRNSTotal Voting Rights
30th May 20247:00 amRNSFY24 Results
14th May 20241:24 pmRNSDirector/PDMR Shareholding
10th May 20247:00 amRNSCFO start date - update
1st May 20244:14 pmRNSTotal Voting Rights
16th Apr 20247:00 amRNSCEO succession
16th Apr 20247:00 amRNSFY24 trading and FY25 outlook update
12th Apr 20243:13 pmRNSDirector/PDMR Shareholding
28th Mar 20245:56 pmRNSTotal Voting Rights
12th Mar 20243:50 pmRNSDirector/PDMR Shareholding
1st Mar 202411:19 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSCFO appointment update
14th Feb 20244:10 pmRNSDirector/PDMR Shareholding
5th Feb 20242:13 pmRNSDirector/PDMR Shareholding
1st Feb 202410:40 amRNSTotal Voting Rights
25th Jan 20247:00 amRNSQ3 FY24 Trading Statement
12th Jan 20241:58 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:13 amRNSTotal Voting Rights
15th Dec 20236:20 pmRNSTransaction in Own Shares
14th Dec 20236:15 pmRNSTransaction in Own Shares
13th Dec 20236:02 pmRNSTransaction in Own Shares
12th Dec 20236:24 pmRNSTransaction in Own Shares
12th Dec 20231:42 pmRNSDirector/PDMR Shareholding
11th Dec 20236:04 pmRNSTransaction in Own Shares
8th Dec 20236:16 pmRNSTransaction in Own Shares
7th Dec 20236:23 pmRNSTransaction in Own Shares
6th Dec 20236:08 pmRNSTransaction in Own Shares
5th Dec 20236:20 pmRNSTransaction in Own Shares
4th Dec 20236:29 pmRNSTransaction in Own Shares
1st Dec 20236:20 pmRNSTransaction in Own Shares
1st Dec 20232:08 pmRNSHolding(s) in Company
1st Dec 20238:00 amRNSBlock listing Interim Review
30th Nov 20234:08 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSHalf-year Report
20th Nov 20236:07 pmRNSTransaction in Own Shares
17th Nov 20236:21 pmRNSTransaction in Own Shares
16th Nov 20236:23 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.